ARWR · Healthcare · $9.2B
$65.07-0.58%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Short Float 10.5% · biweekly · settled 26.05.15
Among 327 Biotechnology peers
Quarterly Revenue Growth
“SHASTA-3·4 임상에서 중성지방 79~81% 감소, 급성췌장염 78~100% 감소라는 압도적 결과가 나왔고 우선심사바우처까지 확보해 승인까”
In the company's words · 2026 3분기 earnings call